UCB

UCB (UCB.BR) * Financial performance in the first half of 2008 in-line with expectations: Revenue as expected down by 11% to EUR 1.7 billion; underlying profitability (recurring EBITDA) reached EUR 358 million (-26%), reported net profit EUR 108 million (-37%). * Integration of Schwarz Pharma completed ahead of schedule: Synergies in the first six months reached EUR 305 million; synergies of 2008 will reach EUR 350 million; targeted synergies of EUR 380 million to be reached almost two years ahead of schedule. * Multiple regulatory milestones and approvals: In the first half of 2008, UCB achieved two approvals (Cimzia®, Crohn's disease and Xyzal® oral solution) in the U.S. and two positive opinions (Neupro®, RLS and Vimpat®, epilepsy) for Europe. * New "SHAPE" initiative: Major global effort to improve competitiveness and profitability by re-allocating EUR 300 million within the next three years. The initiative includes increase ...

UCB (UCB.BR) Brussels, BELGIUM, July 29, 2008 at 6 pm CEST - press release, regulated information: UCB announced today that it received a not-approvable letter from the U.S. Food and Drug Administration (FDA) for lacosamide for the treatment of diabetic neuropathic pain in adults.

UCB (UCB.BR) The European marketing authorisation application for Cimzia® has been filed. Subject to approval, Cimzia® will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.

UCB (UCB.BR) Brussels, BELGIUM, June 26, 2008 - Press release: regulated information UCB announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants a marketing authorisation for lacosamide, proposed trade name Vimpat(TM), for the adjunctive treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy, aged 16 years and older.

UCB (UCB.BR) * Results in proof of concept trial encourage further analysis * Promising side effect profile observed

UCB (UCB.BR) * Otsuka and UCB have agreed to co-promote UCB's anti epileptic drug, Keppra® and its anti-TNF alpha drug, Cimzia® in Japan - the second largest pharmaceutical market in the world. Otsuka will also co-develop new indications.

UCB (UCB.BR) * Period of exclusivity until January 2009 in the US * Pediatric indication filed with FDA

UCB (UCB.BR) Neupro® patches should be stored in the refrigerator. Physicians not to initiate any new patients on Neupro® to prioritise supply for existing patients.